Session » Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Epidemiology and Prognosis

Date: Sunday, November 8, 2015

Time: 2:30PM-4:00PM

Meeting: 2015 ACR/ARHP Annual Meeting

2:30PM-4:00PM: Abstract Number: 986

Application of New EULAR Definitions of Remission in SLE: Durable 1-Year Remission Is Rare

2:30PM-4:00PM: Abstract Number: 989

Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis

2:30PM-4:00PM: Abstract Number: 988

Factors Associated with Renal Remission, Relapse and Long-Term Renal Function Decline in Lupus Nephritis Treated with Combined Prednisolone and Mycophenolate Mofetil (MMF) or Tacrolimus (Tac)

2:30PM-4:00PM: Abstract Number: 985

Improved Survival in Systemic Lupus Erythematosus: A Population-Based Study

2:30PM-4:00PM: Abstract Number: 990

Performance of the Systemic Lupus International Collaborating Clinic Classification Criteria Versus the 1982 and Revised 1997 American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus: A Population-Based Study

2:30PM-4:00PM: Abstract Number: 987

Pre-Emptive Renal Transplantation Among End Stage Renal Disease Patients with and without SLE

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].